TC BioPharm Limited Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

NATURE AND DESCRIPTION OF BUSINESS (Details Narrative)

NATURE AND DESCRIPTION OF BUSINESS (Details Narrative)																				1 Months Ended	12 Months Ended
NATURE AND DESCRIPTION OF BUSINESS (Details Narrative)	Mar. 12, 2024 shares	Dec. 18, 2023 USD ($) $ / shares shares	Dec. 18, 2023 GBP (£) £ / shares shares	Dec. 15, 2023	Sep. 05, 2023 $ / shares	Sep. 05, 2023 £ / shares	Aug. 30, 2023 USD ($) shares	Aug. 30, 2023 GBP (£) shares	Mar. 27, 2023 USD ($) $ / shares shares	Mar. 27, 2023 GBP (£)	Nov. 27, 2022 USD ($) $ / shares shares	Nov. 27, 2022 GBP (£)	Nov. 24, 2022 shares	Nov. 15, 2022 shares	Jun. 08, 2022 USD ($) shares	Jun. 08, 2022 GBP (£) shares	Feb. 10, 2022 USD ($) $ / shares shares	Feb. 10, 2022 EUR (€) shares	Feb. 10, 2022 GBP (£) shares	Aug. 30, 2023 shares	Dec. 31, 2023 GBP (£) shares	Dec. 31, 2022 GBP (£) shares	Mar. 22, 2024 USD ($)	Mar. 22, 2024 GBP (£)	Aug. 09, 2022 shares	Jun. 08, 2022 GBP (£)
Stock split ratio desctiption				ordinary shares from one ADS representing one ordinary share to one ADS representing 20 ordinary shares
Issuance of shares																	3,164	3,164	3,164
Issuance of ordinary shares															230,000	230,000	63,280	63,280	63,280
Nominal value \| £																					£ 5,233,113	£ 16,799,828
Gross proceeds of warrants \| £																					5,127,260	18,806,153
Proceeds from warrant exercises							$ 2,800,000	£ 2,200,000
Warrant to purchase of common stock									140,000								6,278
Conversion of loan \| $																	$ 13,400,000
Sale of stock \| £																£ 11,500
Proceeds from issuance of ordinary shares															$ 4,600,000	3,700,000					4,186,862	3,369,877
Offering expenses															800,000											£ 600,000
Other Expenses															$ 800,000	£ 600,000
Warrant exercise price per share \| $ / shares									$ 100
Warrant exercise price decrease \| (per share)		$ 1.264	£ 1.00		$ 2.00	£ 1.5814			$ 35
Warrants outstanding																									233,560
Cash and cash equivalents \| £																					2,462,609	4,808,060
Working capital \| £																					1,000,000.0
Net cash used in operating activities \| £																					10,544,870	15,292,297
Net loss \| £																					5,906,953	£ 1,313,601
Subsequent Event [Member]
Issuance of ordinary shares	623,750
Cash																							$ 1,700,000	£ 1,400,000
Securities First Purchase Agreement [Member]
Sale of stock \| £												£ 7,750
Securities First Purchase Agreement [Member] \| Series A Ordinary Warrant [Member]
Warrant to purchase of common stock											73,500
Securities First Purchase Agreement [Member] \| Series B Ordinary Warrant [Member]
Warrant to purchase of common stock											73,500
Securities Second Purchase Agreement [Member]
Sale of stock \| £										£ 10,750
Proceeds from issuance of ordinary shares \| $									$ 4,600,000
Other Expenses \| $									$ 900,000
Securities Second Purchase Agreement [Member] \| Series C Ordinary Warrant [Member]
Warrant to purchase of common stock									171,875
Securities Second Purchase Agreement [Member] \| Series E Purchase Warrant [Member]
Warrant to purchase of common stock		1,750,000
Agreement [Member]
Gross proceeds of warrants \| £																					£ 2,800,000
Warrant to purchase of common stock							23,391	23,391												23,391
Warrant expiration term							5 years 6 months	5 years 6 months												5 years 6 months
Securities Third Purchase Agreement [Member]
Issuance of ordinary shares		1,500,000	1,500,000
Warrant to purchase of common stock		623,750
Sale of stock \| £			£ 75,000
Proceeds from issuance of ordinary shares \| $		$ 3,500,000
Purchase price of warrant \| $ / shares		$ 2.00
Warrant exercise price per share \| £ / shares			£ 1.5814			£ 7.00
Warrant expiration term		5 years
Common Stock [Member]
Issuance of ordinary shares													3	21							19,620,130	559,006
Nominal value																		€ 31,640	£ 31,640		£ 1,962	£ 202,017
Net loss \| £
Common Stock [Member] \| Securities Third Purchase Agreement [Member]
Issuance of ordinary shares		2,625,000	2,625,000
Prefunded Warrant [Member] \| Securities First Purchase Agreement [Member]
Warrant to purchase of common stock											65,750
Purchase price of warrant \| $ / shares											$ 100
Prefunded Warrant [Member] \| Securities Second Purchase Agreement [Member]
Warrant to purchase of common stock									161,125
Purchase price of warrant \| $ / shares									$ 32
Prefunded Warrant [Member] \| Securities Third Purchase Agreement [Member]
Warrant to purchase of common stock		1,675,000
Purchase price of warrant \| $ / shares		$ 1.999
Ordinary Warrant [Member]
Gross proceeds of warrants											$ 7,400,000	£ 6,100,000
Ordinary Warrant [Member] \| Securities First Purchase Agreement [Member]
Purchase price of warrant \| $ / shares											$ 99.98
Ordinary Warrant [Member] \| Securities Second Purchase Agreement [Member]
[custom:PrefundedWarrants] \| $ / shares									$ 31.98
Ordinary Warrant [Member] \| Securities Third Purchase Agreement [Member]
Warrant exercise price per share \| $ / shares		$ 0.001
Placement Agent Warrant [Member] \| Securities Second Purchase Agreement [Member]
Warrant to purchase of common stock									12,891
Pre-Funded Warrants [Member] \| Securities Second Purchase Agreement [Member]
Proceeds from issuance of ordinary shares \| $									$ 4,900,000
Other Expenses \| $									$ 600,000
Series A Warrant Holders [Member] \| Agreement [Member]
Warrants outstanding							70,000	70,000												70,000
Series B Warrant Holders [Member] \| Agreement [Member]
Warrants outstanding							70,000	70,000												70,000
Series C Warrant Holders [Member] \| Agreement [Member]
Warrants outstanding							171,875	171,875												171,875
Series D Warrants [Member] \| Agreement [Member]
Warrant to purchase of common stock							623,750	623,750												623,750
Number of warrants issued																				623,750
Warrant [Member] \| Securities Third Purchase Agreement [Member]
Issuance of ordinary shares		33,500,000	33,500,000
Warrant to purchase of common stock		35,000,000
IPO [Member]
Issuance of shares																	4,117	4,117	4,117
Issuance of ordinary shares																	82,353	82,353	82,353
Gross proceeds of warrants \| £																			£ 9,470
Proceeds from warrant exercises																	$ 17,500,000		12,800,000
Underwriter fees																	$ 3,000,000.0		2,200,000
Purchase price of warrant \| $ / shares																	$ 4,250
IPO [Member] \| Common Stock [Member]
Nominal value																		€ 41,176	£ 41,176